Experience Matters
Providing expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia.
Welcome to Lucid Health Consulting
With over 30 years of Health Economics, Pricing & Reimbursement, Strategic Market Access and Health Technology Assessment experience, we have helped many organisations navigate the complexities of the Australian regulatory environment and achieve market access.
We have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.
Let us show you how our strategic approach and team experience can help you achieve market access in Australia.
How we can help your business?
What’s New
Read our articles, find out about our upcoming webinars and speaking engagements for the latest industry insights.
ISPOR Europe 2023, 12-15 November, with our Poster.
The ISPOR Europe 2023 conference for 2023 was held this year in Copenhagen, Denmark on 12 – 15 November, with the theme: "HEOR at the Nexus of Policy and Science" The road to policy and clinical integration for health technologies is filled with diverse and...
9th Annual Drugs & Devices Australia Webinar – 2023
9th Annual Drugs & Devices Australia Webinar - 2023 When: 30 November, 8:30am AEST and 29 November 2023, 1:30pm PST. Please join our Director, George Papadopoulos and Sarah Griffin, Director of MedTechnique Consulting for their annual Drugs & Devices...
New Strategic Partnership with Vista Health in Asia Pacific Region
Lucid Health Consulting and Vista Health Forge Strategic Partnership across the Asia Pacific Region We are thrilled to announce a strategic partnership with Vista Health aimed at fortifying our joint commitment to delivering unparalleled health economics, HTA,...
What our clients are saying.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.